Advertisement
UK markets open in 6 hours 50 minutes

  • NIKKEI 225

    37,552.16
    0.00 (0.00%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.46
    +0.10 (+0.12%)
     

  • GOLD FUTURES

    2,337.00
    -5.10 (-0.22%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,516.14
    -127.49 (-0.24%)
     

  • CMC Crypto 200

    1,429.29
    +14.53 (+1.03%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

BeiGene, Novartis partner to develop cancer drug tislelizumab

Reuters
·1-min read
People enter a building of biotechnology firm BeiGene Ltd at the Suzhou Industrial Park in Suzhou

(Reuters) - China-based biotechnology company BeiGene Ltd said on Monday it will partner with Swiss firm Novartis AG to develop, manufacture and commercialize its cancer drug tislelizumab.

Under terms of the deal, BeiGene will earn $650 million in an upfront cash payment from Novartis, and up to $1.55 billion in milestone payments and royalties on product sales, the Beijing-headquartered company said in a statement.

Novartis will co-develop and commercialize tislelizumab in North America, the European Union, Japan and six other countries, BeiGene said, adding BeiGene would be responsible for funding ongoing clinical trials of tislelizumab.

Both parties have freedom to conduct combination trials globally under the deal, it said.

ADVERTISEMENT

Chinese regulators last June accepted Hong Kong-listed BeiGene's new drug application of tislelizumab combining with chemotherapy for treatment of patients with advanced non-squamous non-small cell lung cancer.

(Reporting by Derek Francis in Bengaluru; editing by Richard Pullin)